NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $7.57 +0.08 (+1.01%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$7.56 0.00 (-0.01%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AUPH alerts:Sign Up Key Stats Today's Range$7.45▼$7.6150-Day Range$7.48▼$8.6452-Week Range$5.20▼$10.67Volume1.01 million shsAverage Volume1.37 million shsMarket Capitalization$1.02 billionP/E Ratio27.02Dividend YieldN/APrice Target$11.50Consensus RatingBuy Company Overview Aurinia Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company dedicated to developing and commercializing novel therapies for autoimmune and inflammatory diseases. Its flagship product, Lupkynis (voclosporin), is approved for the treatment of lupus nephritis, a severe kidney inflammation that arises from systemic lupus erythematosus. Aurinia’s research pipeline also encompasses investigational candidates targeting other immune‐mediated conditions, leveraging proprietary small‐molecule platform technologies to modulate key pathways involved in disease progression. Since its founding in 1993 and its relocation of global headquarters to Victoria, British Columbia, Aurinia has expanded its operational footprint with a strategic presence in the United States and Europe. The company collaborates with contract research organizations and clinical centers worldwide to advance its studies, ensuring robust patient enrollment and regulatory engagement across major markets. Aurinia’s manufacturing partnerships support scalable production of its lead therapy, while its commercial infrastructure continues to evolve as Lupkynis reaches new patient populations. Under the leadership of an experienced management team with deep expertise in biopharmaceutical development and commercialization, Aurinia is committed to achieving sustainable growth through disciplined clinical execution and strategic alliances. The company’s board of directors includes industry veterans from both large pharmaceutical companies and innovative biotech startups. Aurinia remains focused on delivering transformative treatments to patients with high unmet medical needs and on building long‐term shareholder value through scientific innovation and operational excellence.AI Generated. May Contain Errors. Read More Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreAUPH MarketRank™: Aurinia Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 346th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAurinia Pharmaceuticals has received no research coverage in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth409.09% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is 27.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is 27.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.43.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 2.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aurinia Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.82% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.82% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 0.29%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.42 News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 32 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat Follows3 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Stock News HeadlinesAurinia Pharmaceuticals (AUPH) Gets a Buy from TD CowenJuly 3 at 5:45 PM | theglobeandmail.comAurinia Pharmaceuticals Inc News (AUPH) - Investing.comJuly 3 at 5:39 AM | investing.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 5 at 2:00 AM | Brownstone Research (Ad)AUPH - Aurinia Pharmaceuticals Inc News - MorningstarJuly 2 at 4:47 AM | morningstar.comMAurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)June 30, 2025 | businesswire.comAurinia Pharmaceuticals Inc (AUPH) Announces Webcast for AUR200 Phase 1 Study Results | AUPH ...June 29, 2025 | gurufocus.comAurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025June 29, 2025 | financialpost.comFAurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025June 29, 2025 | businesswire.comSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $8.98 at the start of the year. Since then, AUPH stock has decreased by 15.7% and is now trading at $7.5660. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its earnings results on Monday, May, 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.08. The biotechnology company earned $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a trailing twelve-month return on equity of 14.27% and a net margin of 16.11%. Read the conference call transcript. Who are Aurinia Pharmaceuticals' major shareholders? Top institutional investors of Aurinia Pharmaceuticals include City Center Advisors LLC (0.02%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/12/2025Today7/05/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUPH CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$13.00 Low Stock Price Target$10.00 Potential Upside/Downside+52.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.28 Trailing P/E Ratio27.02 Forward P/E Ratio68.78 P/E GrowthN/ANet Income$5.75 million Net Margins16.11% Pretax Margin16.91% Return on Equity14.27% Return on Assets9.93% Debt Debt-to-Equity Ratio0.16 Current Ratio5.93 Quick Ratio5.26 Sales & Book Value Annual Sales$235.13 million Price / Sales4.35 Cash Flow$0.31 per share Price / Cash Flow24.61 Book Value$2.68 per share Price / Book2.82Miscellaneous Outstanding Shares135,100,000Free Float118,621,000Market Cap$1.02 billion OptionableOptionable Beta1.16 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AUPH) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.